208.4 📌 章末速蚘

  • SARS-CoV-2: ssRNA β-coronavirus, ACE2 + TMPRSS2 receptors
  • Variants (2024-2025): JN.1 → KP.3 → ongoing Omicron evolution
  • Spectrum: mild URI → ARDS → multi-organ failure
  • Thromboembolism (DVT, PE, stroke, MI) prominent
  • MIS-C / MIS-A post-COVID multi-system inflammation
  • Long COVID 1-3% — fatigue, brain fog, dyspnea, POTS, anxiety
  • Treatment outpatient high-risk < 5d: Paxlovid (drug interactions!) > remdesivir > molnupiravir
  • Hospitalized: remdesivir + dexamethasone; tocilizumab/baricitinib severe
  • Pemivibart = mAb for immunocompromise PrEP (2024)
  • Vaccines: annual mRNA monovalent (KP.2-targeted 2024-2025)
  • WHO PHEIC ended May 2023; endemic ongoing
  • 盧醫垫 hint: 高 risk 老/慢病/å­•å©Š — annual COVID + flu + RSV vaccines + Paxlovid early empirical